医学
心肌梗塞
内科学
危险系数
心脏病学
安慰剂
临床终点
载脂蛋白B
冲程（发动机）
置信区间
胆固醇
随机对照试验
机械工程
替代医学
病理
工程类
作者
C. Michael Gibson,Danielle Duffy,Serge Korjian,M. Cecilia Bahit,Gerald Chi,John H. Alexander,A. Michael Lincoff,Mark Heise,Pierluigi Tricoci,Lawrence I. Deckelbaum,Sojaita Jenny Mears,José Carlos Nicolau,Renato D. Lópes,Béla Merkely,Basil S. Lewis,Jan H. Cornel,Jarosław Trębacz,Alexander Parkhomenko,Peter Libby,Frank M. Sacks
标识
DOI：10.1056/nejmoa2400969
摘要
Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk of cardiovascular events. CSL112 is human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity. Whether infusions of CSL112 can reduce the risk of recurrent cardiovascular events after acute myocardial infarction is unclear.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
热心市民小红花
SYLH
ED
眼睛大雨筠
彭于彦祖
pluto
昏睡的蟠桃
wu8577
Billy
现代的访曼
pcr163
Rondab
搞怪莫茗
iNk
yznfly
LaTeXer
YH
yydragen
卡拉蜜儿
bxyyy
皖公网安备34019202002308
